Eton Pharmaceuticals FY2026 Revenue expected to be more than $120.000M vs $113.804M Est

Benzinga Newsdesk www.benzinga.com Positive 70.9%

Neg 0% Neu 0% Pos 70.9%

Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $120.000M vs $113.804M Est

Comments

No comments yet. Be the first!